DDInter1484 DDInter1376
Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Plicamycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gatifloxacin
Plicamycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Plicamycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epoprostenol
Plicamycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Plicamycin {u} may lead to a major life threatening interaction when taken with {v} Ibritumomab tiuxetan
Plicamycin {u} may lead to a major life threatening interaction when taken with {v} Regorafenib
Plicamycin may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin
Plicamycin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Plicamycin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Plicamycin may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Plicamycin may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan
Plicamycin may lead to a major life threatening interaction when taken with Regorafenib